Neurocrine Holds Annual Meeting, Approves Key Matters

Neurocrine ( (NBIX) ) has shared an update.

On May 21, 2025, Neurocrine held its Annual Meeting where stockholders voted on several key matters. The election of four Class II Directors was confirmed, and the compensation for named executive officers was approved. Additionally, the 2025 Plan and the Amended and Restated ESPP were sanctioned, and Ernst & Young LLP’s appointment as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.

The most recent analyst rating on (NBIX) stock is a Buy with a $150.00 price target. To see the full list of analyst forecasts on Neurocrine stock, see the NBIX Stock Forecast page.

Spark’s Take on NBIX Stock

According to Spark, TipRanks’ AI Analyst, NBIX is a Outperform.

Neurocrine’s stock score reflects its strong financial performance and promising developments in R&D, tempered by valuation concerns and operational challenges. While the company’s financial stability and growth potential are significant strengths, high P/E ratio and reimbursement challenges pose risks. The technical analysis suggests mixed signals, indicating potential volatility.

To see Spark’s full report on NBIX stock, click here.

More about Neurocrine

Average Trading Volume: 1,556,531

Technical Sentiment Signal: Hold

Current Market Cap: $12.17B

For detailed information about NBIX stock, go to TipRanks’ Stock Analysis page.